QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
NASDAQ:PHAS

PhaseBio Pharmaceuticals SEC Filings & 10K Form

$0.81
-0.09 (-9.98%)
(As of 05/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.80
$0.90
50-Day Range
$0.91
$1.68
52-Week Range
$0.80
$4.24
Volume
757,116 shs
Average Volume
577,064 shs
Market Capitalization
$39.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.98

PhaseBio Pharmaceuticals (NASDAQ:PHAS) SEC Filings

DateFilerForm TypeView
05/16/2022
5:06 AM
PhaseBio Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/16/2022
5:04 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/22/2022
3:13 PM
PhaseBio Pharmaceuticals (Filer)
Form DEF 14A
09/15/2021
7:15 AM
Humphries William D. (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2021
7:14 AM
Humphries William D. (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
09/15/2021
7:04 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/30/2021
4:52 PM
Mow Jonathan P (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2021
3:24 PM
Hutson Nancy J (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2021
5:07 PM
PhaseBio Pharmaceuticals (Issuer)
Thorp Clay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2021
7:03 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/10/2021
6:57 AM
PhaseBio Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
07/14/2021
6:06 PM
Arnold Susan Elizabeth (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2021
7:13 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/04/2021
5:17 PM
PhaseBio Pharmaceuticals (Issuer)
van den Broek Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2021
5:14 PM
PhaseBio Pharmaceuticals (Issuer)
Sapir Alex (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2021
5:08 PM
HARRIGAN EDMUND (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2021
5:07 PM
Klein Peter Justin (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2021
5:06 PM
Loewy Caroline M (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2021
5:05 PM
Hutson Nancy J (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2021
5:03 PM
PhaseBio Pharmaceuticals (Issuer)
Thorp Clay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2021
5:11 PM
PhaseBio Pharmaceuticals (Issuer)
Sharp John P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2021
5:11 PM
Burkhardt Glen (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2021
5:10 PM
Mow Jonathan P (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2021
5:10 PM
PhaseBio Pharmaceuticals (Issuer)
York Michael (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2021
5:09 PM
Arnold Susan Elizabeth (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2021
5:09 PM
Hanson Kristopher (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2021
1:25 PM
PhaseBio Pharmaceuticals (Subject)
Rosalind Advisors, Inc. (Filed by)
Form SC 13G
03/24/2021
3:30 PM
PhaseBio Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13G
03/17/2021
4:07 PM
PhaseBio Pharmaceuticals (Filer)
Form 424B5
03/15/2021
7:42 AM
PhaseBio Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/15/2021
7:18 AM
PhaseBio Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/15/2021
7:10 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/11/2021
7:08 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/09/2021
3:50 PM
Arnold Susan Elizabeth (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/09/2021
3:48 PM
PhaseBio Pharmaceuticals (Issuer)
Sharp John P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/09/2021
3:45 PM
Lee John Sang (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/28/2021
7:11 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2021
3:11 PM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/11/2021
8:10 AM
PhaseBio Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
12/04/2020
2:53 PM
HARRIGAN EDMUND (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2020
3:04 PM
PhaseBio Pharmaceuticals (Issuer)
Thorp Clay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
5:43 PM
PhaseBio Pharmaceuticals (Issuer)
Sharp John P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
5:42 PM
Hanson Kristopher (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
5:40 PM
PhaseBio Pharmaceuticals (Issuer)
York Michael (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
5:38 PM
Ballance David James (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
5:36 PM
Arnold Susan Elizabeth (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
5:34 PM
Mow Jonathan P (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
5:27 PM
Burkhardt Glen (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/18/2020
6:19 PM
PhaseBio Pharmaceuticals (Issuer)
Thorp Clay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2020
3:19 PM
PhaseBio Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/23/2020
7:20 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/06/2020
7:09 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/05/2020
8:08 PM
Arnold Susan Elizabeth (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/24/2020
6:04 PM
Mow Jonathan P (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/17/2020
7:15 PM
PhaseBio Pharmaceuticals (Issuer)
Sharp John P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/11/2020
3:22 PM
PhaseBio Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/11/2020
3:09 PM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/16/2020
3:10 PM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2020
6:02 PM
PhaseBio Pharmaceuticals (Issuer)
Thorp Clay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2020
6:00 PM
Klein Peter Justin (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2020
5:58 PM
PhaseBio Pharmaceuticals (Issuer)
van den Broek Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2020
5:57 PM
Hutson Nancy J (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2020
5:55 PM
HARRIGAN EDMUND (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2020
5:52 PM
Loewy Caroline M (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2020
5:39 PM
PhaseBio Pharmaceuticals (Issuer)
Sapir Alex (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2020
3:36 PM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/12/2020
3:44 PM
PhaseBio Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
03/30/2020
7:29 AM
PhaseBio Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/30/2020
7:20 AM
PhaseBio Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/30/2020
7:08 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2020
5:51 PM
Mow Jonathan P (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
5:51 PM
Ballance David James (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
5:51 PM
Arnold Susan Elizabeth (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
5:50 PM
Lee John Sang (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
5:50 PM
PhaseBio Pharmaceuticals (Issuer)
Sapir Alex (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
5:50 PM
Hanson Kristopher (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
5:49 PM
PhaseBio Pharmaceuticals (Issuer)
Sharp John P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
5:49 PM
PhaseBio Pharmaceuticals (Issuer)
York Michael (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
5:43 PM
PhaseBio Pharmaceuticals (Issuer)
Sapir Alex (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
02/14/2020
5:38 PM
Burkhardt Glen (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2020
5:34 PM
Burkhardt Glen (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
02/14/2020
12:49 PM
PhaseBio Pharmaceuticals (Subject)
Rock Springs Capital Management LP (Filed by)
Form SC 13G/A
02/11/2020
7:08 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/04/2020
3:08 PM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2020
2:36 PM
PhaseBio Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
01/17/2020
12:57 PM
JOHNSON & JOHNSON (Filed by)
PhaseBio Pharmaceuticals (Subject)
Form SC 13G/A
01/13/2020
3:07 PM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/10/2020
8:07 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2020
11:15 PM
PhaseBio Pharmaceuticals (Filer)
Form EFFECT
12/27/2019
4:28 PM
PhaseBio Pharmaceuticals (Filer)
Form S-3
Registration statement under Securities Act of 1933  
11/14/2019
7:16 AM
PhaseBio Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/14/2019
7:16 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2019
7:03 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/07/2019
6:11 PM
Hanson Kristopher (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/07/2019
6:07 PM
Hanson Kristopher (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
09/24/2019
3:05 PM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/10/2019
3:10 PM
Mow Jonathan P (Reporting)
PhaseBio Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2019
6:42 PM
PhaseBio Pharmaceuticals (Issuer)
Sharp John P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2019
8:06 AM
PhaseBio Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2019
8:05 AM
PhaseBio Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.